Free tool
FAERS Monitor: Alimta
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021462 or its brand name (Alimta, Pemetrexed Disodium). Reports on generic versions are filed under their own applications.
Reports
16,927
Serious
15,517
92% of reports
Hospitalization
8,359
Death reported
3,495
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- malignant neoplasm progression1,432
- off label use1,238
- death939
- nausea915
- anaemia873
- diarrhoea851
- pancytopenia821
- neutropenia729
- fatigue727
- thrombocytopenia685
- rash681
- dyspnoea670
- pyrexia640
- vomiting640
- asthenia580
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 131 |
| 2005 | 406 |
| 2006 | 368 |
| 2007 | 296 |
| 2008 | 279 |
| 2009 | 469 |
| 2010 | 624 |
| 2011 | 658 |
| 2012 | 952 |
| 2013 | 541 |
| 2014 | 585 |
| 2015 | 1,671 |
| 2016 | 556 |
| 2017 | 736 |
| 2018 | 958 |
| 2019 | 1,371 |
| 2020 | 1,268 |
| 2021 | 1,128 |
| 2022 | 873 |
| 2023 | 691 |
| 2024 | 840 |
| 2025 | 866 |
| 2026 | 660 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,037,232 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| pancytopeniaSignal | 821 | 18.5 | 17.3 | 13,419 |
| malignant neoplasm progressionSignal | 1,432 | 17.6 | 16.7 | 22,209 |
| thrombocytopeniaSignal | 685 | 7.7 | 7.1 | 3,951 |
| neutropeniaSignal | 729 | 6.7 | 6.2 | 3,528 |
| anaemiaSignal | 873 | 5.7 | 5.4 | 3,402 |
| pyrexiaSignal | 640 | 2.3 | 2.1 | 476 |
| rash | 681 | 1.9 | 1.8 | 317 |
| asthenia | 580 | 1.9 | 1.8 | 258 |
| off label use | 1,238 | 1.8 | 1.7 | 421 |
| vomiting | 640 | 1.7 | 1.6 | 184 |
| diarrhoea | 851 | 1.6 | 1.5 | 218 |
| dyspnoea | 670 | 1.5 | 1.4 | 103 |
| nausea | 915 | 1.4 | 1.3 | 126 |
| death | 939 | 1.4 | 1.3 | 90 |
| fatigue | 727 | 1.2 | 1.1 | 17 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.